The Burden of Human African Trypanosomiasis

Human African trypanosomiasis (HAT, or sleeping sickness) is a protozoan parasitic infection caused by Trypanosoma brucei rhodesiense or Trypanosoma brucei gambiense. These are neglected tropical diseases, and T.b. rhodesiense HAT is a zoonosis. We review current knowledge on the burden of HAT in sub-Saharan Africa, with an emphasis on the disability-adjusted life year (DALY), data sources, and methodological issues relating to the use of this metric for assessing the burden of this disease. We highlight areas where data are lacking to properly quantify the impact of these diseases, mainly relating to quantifying under-reporting and disability associated with infection, and challenge the HAT research community to tackle the neglect in data gathering to enable better evidence-based assessments of burden using DALYs or other appropriate measures.

[1]  J. Sahani,et al.  Knowledge, attitudes and practices on tsetse and sleeping sickness among communities living in and around Serengeti National Park, Tanzania. , 2009, Tanzania health research bulletin.

[2]  P. Kennedy.  Diagnosing central nervous system trypanosomiasis: two stage or not to stage? , 2008, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[3]  S. Brooker,et al.  The health impact of polyparasitism in humans: are we under-estimating the burden of parasitic diseases? , 2008, Parasitology.

[4]  Mark EJ Woolhouse,et al.  Estimating the burden of rhodesiense sleeping sickness during an outbreak in Serere, eastern Uganda , 2008, BMC public health.

[5]  L. Pinoges,et al.  Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study , 2008, BMJ : British Medical Journal.

[6]  Z. Pawłowski.  Control of neurocysticercosis by routine medical and veterinary services. , 2008, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[7]  C. King,et al.  Asymmetries of Poverty: Why Global Burden of Disease Valuations Underestimate the Burden of Neglected Tropical Diseases , 2008, PLoS neglected tropical diseases.

[8]  F. Checchi,et al.  Estimates of the duration of the early and late stage of gambiense sleeping sickness , 2008, BMC infectious diseases.

[9]  M. Boelaert,et al.  Eflornithine is a cost‐effective alternative to melarsoprol for the treatment of second‐stage human West African trypanosomiasis in Caxito, Angola , 2008, Tropical medicine & international health : TM & IH.

[10]  P. Simarro,et al.  Eliminating Human African Trypanosomiasis: Where Do We Stand and What Comes Next> , 2008, PLoS medicine.

[11]  C. Burri,et al.  Sleeping hearts: the role of the heart in sleeping sickness (human African trypanosomiasis) , 2007, Tropical medicine & international health : TM & IH.

[12]  J. Vega,et al.  Short communication: The cost‐effectiveness of cutaneous leishmaniasis patient management during an epidemic in Chaparral, Colombia in 2004 , 2007, Tropical medicine & international health : TM & IH.

[13]  A. Prüss-Ustün,et al.  The Global Burden of Disease Assessments—WHO Is Responsible? , 2007, PLoS neglected tropical diseases.

[14]  F. Chappuis.  Melarsoprol-free drug combinations for second-stage Gambian sleeping sickness: the way to go. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  Majid Ezzati,et al.  Measuring the Burden of Neglected Tropical Diseases: The Global Burden of Disease Framework , 2007, PLoS neglected tropical diseases.

[16]  M. Boelaert,et al.  Cost-effectiveness of Algorithms for Confirmation Test of Human African Trypanosomiasis , 2007, Emerging infectious diseases.

[17]  L. Rombo,et al.  The true burden and risk of cholera: implications for prevention and control. , 2007, The Lancet. Infectious diseases.

[18]  J. Kabasa.  Public-private partnership works to stamp out sleeping sickness in Uganda. , 2007, Trends in parasitology.

[19]  P. Glaziou,et al.  Reaching the global tuberculosis control targets in the Western Pacific Region. , 2007, Bulletin of the World Health Organization.

[20]  M. Boelaert,et al.  Human African Trypanosomiasis in a Rural Community, Democratic Republic of Congo , 2007, Emerging infectious diseases.

[21]  P. Preux,et al.  Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness. , 2007, The Journal of infectious diseases.

[22]  T. Monath.  Yellow fever as an endemic/epidemic disease and priorities for vaccination. , 2006, Bulletin de la Societe de pathologie exotique.

[23]  C. Mathers,et al.  Projections of Global Mortality and Burden of Disease from 2002 to 2030 , 2006, PLoS medicine.

[24]  F. Sassi.  Calculating QALYs, comparing QALY and DALY calculations. , 2006, Health policy and planning.

[25]  L. Savioli,et al.  Reconsidering the underestimated burden caused by neglected tropical diseases. , 2006, Trends in parasitology.

[26]  G. Simo,et al.  High prevalence of Trypanosoma brucei gambiense group 1 in pigs from the Fontem sleeping sickness focus in Cameroon. , 2006, Veterinary parasitology.

[27]  M. Rai,et al.  Serious underreporting of visceral leishmaniasis through passive case reporting in Bihar, India , 2006, Tropical medicine & international health : TM & IH.

[28]  P. Kennedy.  Diagnostic and neuropathogenesis issues in human African trypanosomiasis. , 2006, International journal for parasitology.

[29]  H. Braakman,et al.  Lethal African trypanosomiasis in a traveler: MRI and neuropathology , 2006, Neurology.

[30]  Alan D. Lopez,et al.  Global burden of disease and risk factors , 2006 .

[31]  E. Fèvre,et al.  Sleeping sickness in Uganda: a thin line between two fatal diseases , 2005, BMJ : British Medical Journal.

[32]  J. McDermott,et al.  Quantifying the level of under‐detection of Trypanosoma brucei rhodesiense sleeping sickness cases , 2005, Tropical medicine & international health : TM & IH.

[33]  M. Boelaert,et al.  Trypanosomiasis Control, Democratic Republic of Congo, 1993–2003 , 2005, Emerging infectious diseases.

[34]  F. Chappuis,et al.  Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  E. Fèvre,et al.  A burgeoning epidemic of sleeping sickness in Uganda , 2005, The Lancet.

[36]  E. Fèvre,et al.  The epidemiology of animal bite injuries in Uganda and projections of the burden of rabies , 2005, Tropical medicine & international health : TM & IH.

[37]  M. Meltzer,et al.  Re-evaluating the burden of rabies in Africa and Asia. , 2005, Bulletin of the World Health Organization.

[38]  Alan D. Lopez,et al.  Counting the dead and what they died from: an assessment of the global status of cause of death data. , 2005, Bulletin of the World Health Organization.

[39]  P. Ostergren,et al.  Using burden of disease/cost-effectiveness as an instrument for district health planning: experiences from Uganda. , 2004, Health policy.

[40]  J. Jannin,et al.  Treatment and control of human African trypanosomiasis , 2004, Current opinion in infectious diseases.

[41]  Alan D. Lopez,et al.  Monitoring global health: time for new solutions , 2005, BMJ : British Medical Journal.

[42]  J. Chisi,et al.  Anaemia in human African trypanosomiasis caused by Trypanosoma brucei rhodesiense. , 2004, East African medical journal.

[43]  E. Worrall,et al.  The burden of malaria epidemics and cost-effectiveness of interventions in epidemic situations in Africa. , 2004, The American journal of tropical medicine and hygiene.

[44]  A. Shaw,et al.  Assessing the patterns of health-seeking behaviour and awareness among sleeping-sickness patients in eastern Uganda , 2004, Annals of tropical medicine and parasitology.

[45]  M. Boelaert,et al.  The effectiveness of active population screening and treatment for sleeping sickness control in the Democratic Republic of Congo , 2004, Tropical medicine & international health : TM & IH.

[46]  E. Fèvre,et al.  Reanalyzing the 1900-1920 sleeping sickness epidemic in Uganda. , 2004, Emerging infectious diseases.

[47]  S. Krishna,et al.  Retaking sleeping sickness control in Angola , 2004, Tropical medicine & international health : TM & IH.

[48]  A. Fairlamb.  Chemotherapy of human African trypanosomiasis: current and future prospects. , 2003, Trends in parasitology.

[49]  M. Boelaert,et al.  La maladie de sommeil dans la région Ville de Kinshasa: une analyse rétrospective des données de surveillance sur la période 1996–2000 , 2003 .

[50]  O. Norheim,et al.  Using burden of disease information for health planning in developing countries: the experience from Uganda. , 2003, Social science & medicine.

[51]  C. Burri,et al.  Eflornithine for the treatment of human African trypanosomiasis , 2003, Parasitology Research.

[52]  R. Docampo,et al.  Current chemotherapy of human African trypanosomiasis , 2003, Parasitology Research.

[53]  M. Dumas,et al.  Treatment perspectives for human African trypanosomiasis , 2003, Fundamental & clinical pharmacology.

[54]  L. H. Taylor,et al.  Identifying Reservoirs of Infection: A Conceptual and Practical Challenge , 2002, Emerging infectious diseases.

[55]  P. Simarro,et al.  [Sleeping sickness: one hundred years of control strategy evolution]. , 2002, Bulletin de la Societe de pathologie exotique.

[56]  S. Magez,et al.  Novel primer sequences for polymerase chain reaction-based detection of Trypanosoma brucei gambiense. , 2002, The American journal of tropical medicine and hygiene.

[57]  Alimuddin Zumla.  Drugs for neglected diseases. , 2002, The Lancet. Infectious diseases.

[58]  C. Burri,et al.  Treatment of human African trypanosomiasis--present situation and needs for research and development. , 2002, The Lancet. Infectious diseases.

[59]  Els Torreele,et al.  Drug development for neglected diseases: a deficient market and a public-health policy failure , 2002, The Lancet.

[60]  T. Bossert,et al.  Decentralization of health systems in Ghana, Zambia, Uganda and the Philippines: a comparative analysis of decision space. , 2002, Health policy and planning.

[61]  P. Chiodini,et al.  African Trypanosomiasis in Travelers Returning to the United Kingdom , 2002, Emerging infectious diseases.

[62]  C. Burri,et al.  The phenomenon of treatment failures in Human African Trypanosomiasis , 2001, Tropical medicine & international health : TM & IH.

[63]  J. Fox-Rushby,et al.  Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysis. , 2001, Health Policy and Planning.

[64]  M. Woolhouse,et al.  The origins of a new Trypanosoma brucei rhodesiense sleeping sickness outbreak in eastern Uganda , 2001, The Lancet.

[65]  A. Jeppsson.  Financial priorities under decentralization in Uganda. , 2001, Health policy and planning.

[66]  P. Leggat,et al.  International Public Health: Diseases, Programs, Systems, and Policies , 2001 .

[67]  A. Stanghellini,et al.  The situation of sleeping sickness in Angola: a calamity , 2001, Tropical medicine & international health : TM & IH.

[68]  C. M. Bilenge,et al.  Sleeping sickness resurgence in the DRC: the past decade , 2001, Tropical medicine & international health : TM & IH.

[69]  C. Burri,et al.  Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis , 2001, Tropical medicine & international health : TM & IH.

[70]  A. Moore,et al.  Re‐emergence of epidemic sleeping sickness in southern Sudan , 2001, Tropical medicine & international health : TM & IH.

[71]  R. Ashford,et al.  The leishmaniases as emerging and reemerging zoonoses. , 2000, International journal for parasitology.

[72]  R. Black,et al.  International Public Health : Diseases, Programs, Systems, and Policies , 2000 .

[73]  E. Nord,et al.  The value of DALY life: problems with ethics and validity of disability adjusted life years. , 2000, Leprosy review.

[74]  P. Musgrove,et al.  A critical review of 'a critical review': the methodology of the 1993 World Development Report, 'Investing in Health'. , 2000, Health policy and planning.

[75]  A. Fleming,et al.  Cost-effectiveness of malaria control in sub-Saharan Africa , 1999, The Lancet.

[76]  A. Buguet,et al.  Reversal of the sleep/wake cycle disorder of sleeping sickness after trypanosomicide treatment , 1999, Journal of sleep research.

[77]  D. Levy,et al.  Resurgence of sleeping sickness in Tambura County, Sudan. , 1999, The American journal of tropical medicine and hygiene.

[78]  D. Legros,et al.  Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda. , 1999, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[79]  J. Baker.  Control and surveillance of African trypanosomiasis. Report of a WHO Expert Committee. , 1999, World Health Organization technical report series.

[80]  T. Asonganyi,et al.  Influence of a past history of Gambian sleeping sickness on physical growth, sexual maturity and academic performance of children in Fontem, Cameroon. , 1998, Annals of tropical medicine and parasitology.

[81]  F. Kansiime,et al.  Duration of symptoms and case fatality of sleeping sickness caused by Trypanosoma brucei rhodesiense in Tororo, Uganda. , 1997, East African medical journal.

[82]  C. Murray,et al.  Global burden of disease , 1997, The Lancet.

[83]  J. Barendregt,et al.  Global burden of disease , 1997, The Lancet.

[84]  Alan D. Lopez,et al.  Evidence-Based Health Policy--Lessons from the Global Burden of Disease Study , 1996, Science.

[85]  A. Tait,et al.  The origins, dynamics and generation of Trypanosoma brucei rhodesiense epidemics in East Africa. , 1996, Parasitology today.

[86]  G. Carrin,et al.  Cost-effectiveness analysis of alternative treatments of African gambiense trypanosomiasis in Uganda. , 1995, Health economics.

[87]  Dean T. Jamison,et al.  World development report 1993 : investing in health , 1993 .

[88]  N. Petrelli,et al.  Evaluation of alpha-difluoromethylornithine as a potential chemopreventive agent: tolerance to daily oral administration in humans. , 1993, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[89]  A. Buguet,et al.  Sleep-wake cycle in human African trypanosomiasis. , 1993, Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society.

[90]  F. Milord,et al.  Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness , 1992, The Lancet.

[91]  F. Milord,et al.  The impact of human immunodeficiency virus infection on the epidemiology and treatment of Trypanosoma brucei gambiense sleeping sickness in Nioki, Zaire. , 1992, The American journal of tropical medicine and hygiene.

[92]  B. Allolio,et al.  Fatal toxic epidermal necrolysis during suramin therapy. , 1991, European journal of cancer.

[93]  J. Adams,et al.  HUMAN AFRICAN TRYPANOSOMIASIS (T.b. GAMBIENSE): A STUDY OF 16 FATAL CASES OF SLEEPING SICKNESS WITH SOME OBSERVATIONS ON ACUTE REACTIVE ARSENICAL ENCEPHALOPATHY , 1986, Neuropathology and applied neurobiology.

[94]  M. Dumas,et al.  Treatment of human African trypanosomiasis. , 1983, Bulletin of the World Health Organization.

[95]  D. Godfrey,et al.  Epidemiological studies on the animal reservoir of Gambiense sleeping sickness. Part III. Characterization of trypanozoon stocks by isoenzymes and sensitivity to human serum. , 1982, Tropenmedizin und Parasitologie.

[96]  J. Frézil,et al.  [Symptoms of human trypanosomiasis at the first diagnostic phase in the People Republic of Congo (author's transl)]. , 1982, Medecine tropicale : revue du Corps de sante colonial.

[97]  R. B. Heisch,et al.  Isolation of Trypanosoma rhodesiense from a Bushbuck , 1958, The Central African journal of medicine.

[98]  M. Carrington,et al.  A multiplex PCR that discriminates between Trypanosoma brucei brucei and zoonotic T. b. rhodesiense. , 2008, Experimental parasitology.

[99]  C. Mathers.  Global Burden of Disease , 2008 .

[100]  F. Chappuis,et al.  Clinical presentation and treatment outcome of sleeping sickness in Sudanese pre-school children. , 2007, Acta tropica.

[101]  C. Burri,et al.  Clinical aspects of 2541 patients with second stage human African trypanosomiasis. , 2006, Acta tropica.

[102]  Human African trypanosomiasis (sleeping sickness): epidemiological update. , 2006, Releve epidemiologique hebdomadaire.

[103]  Alan D. Lopez,et al.  The Burden of Disease and Mortality by Condition: Data, Methods, and Results for 2001 -- Global Burden of Disease and Risk Factors , 2006 .

[104]  S. Cleaveland.  The control of neglected zoonotic diseases A route to poverty alleviation , 2006 .

[105]  C. Johnson.  International Public Health: Diseases, Programs, Systems, and Policies , 2006 .

[106]  A. Hyder,et al.  Measures of Health and Disease in Populations , 2005 .

[107]  V. Pentreath,et al.  Pathogenesis of human African trypanosomiasis , 2004 .

[108]  M. Miles,et al.  Tsetse genetics: applications to biology and systematics. , 2004 .

[109]  M. Miles,et al.  Economics of African trypanosomiasis. , 2004 .

[110]  J. Jannin,et al.  Le concept de maladie négligée , 2003 .

[111]  D. Fryback,et al.  HALYS and QALYS and DALYS, Oh My: similarities and differences in summary measures of population Health. , 2002, Annual review of public health.

[112]  P. Lucas,et al.  Maladie du sommeil: cent ans d'évolution des stratégies de lutte. , 2002 .

[113]  P. Simarro,et al.  Control of human African trypanosomiasis in the Quiçama focus, Angola. , 2002, Bulletin of the World Health Organization.

[114]  Peter E. Hilsenrath,et al.  The World Health Report 2000 , 2002 .

[115]  A. Shaw,et al.  Analytical tools for planning cost-effective surveillance in Gambiense sleeping sickness. , 2001, Medecine tropicale : revue du Corps de sante colonial.

[116]  H. Méda,et al.  The epidemiology and control of human African trypanosomiasis. , 2001, Advances in parasitology.

[117]  S. Welburn,et al.  Sleeping sickness: a tale of two diseases. , 2001, Trends in parasitology.

[118]  L. Budd,et al.  DFID-funded Tsetse and Trypanosomosis research and development since 1980. Economic Analysis Vol.2. Natural Resources International Limited, Aylesford, UK. [Joint funded by LPP, AHP and NRSP] , 2000 .

[119]  A. Mills,et al.  Economic analysis of malaria control in Sub-Saharan Africa , 2000 .

[120]  Patricia M. Kristjanson,et al.  MEASURING THE COSTS OF AFRICAN ANIMAL TRYPANOSOMOSIS, THE POTENTIAL BENEFITS OF CONTROL AND RETURNS TO RESEARCH , 1999 .

[121]  B. Swallow.  Impacts of trypanosomiasis on African agriculture. , 1999 .

[122]  M. Dumas,et al.  Clinical aspects of human African trypanosomiasis , 1999 .

[123]  H. Bekedam,et al.  A critical review of priority setting in the health sector: the methodology of the 1993 World Development Report. , 1998, Health policy and planning.

[124]  C. Laveissière,et al.  Dépistage de la maladie du sommeil: efficacité comparée des équipes mobiles et des agents de santé communautaires. , 1998 .

[125]  V. Lin.  Investing in Health Research and Development: Report of the Ad Hoc Committee on Health Research Relating to Future Intervention Options World Health Organization, Geneva, 1996 , 1997 .

[126]  Alan D. Lopez,et al.  Global health statistics: a compendium of incidence prevalence and mortality estimates for over 200 conditions. , 1996 .

[127]  J. Murray,et al.  The Global Burden of Disease , 1996 .

[128]  BOMBAY CALCUrIA,et al.  World development report 1993--investing in health. , 1993, Communicable disease report. CDR weekly.

[129]  J. Roché,et al.  La lutte contre la trypanosomiase humaine africaine dans le foyer de Luba en Guinée équatoriale: bilan de trois méthodes. , 1991 .

[130]  F. Doua,et al.  [The different present-day clinical picture of human African trypanosomiasis caused by T. b. gambiense. Analysis of 300 cases from a focus in Daloa, Ivory Coast]. , 1988, Bulletin de la Societe de pathologie exotique et de ses filiales.

[131]  J. Gouteux,et al.  Le coût du traitement individuel de la trypanosomiase à T. B. GAMBIENSE dans le foyer du Niari (Congo) , 1987 .

[132]  L Haller,et al.  Clinical and pathological aspects of human African trypanosomiasis (T. b. gambiense) with particular reference to reactive arsenical encephalopathy. , 1986, The American journal of tropical medicine and hygiene.

[133]  R. Cramet.  [Sleeping sickness in children and its long term after-effects. Apropos 110 personal observations at Fontem Hospital (Cameroon)]. , 1982, Medecine tropicale : revue du Corps de sante colonial.

[134]  R. Geigy,et al.  Sleeping sickness survey in Musoma district, Tanzania. IV. Examination of wild mammals as a potential reservoir for T.rhodesiense. , 1971, Acta tropica.

[135]  Hugh Waddell Mulligan,et al.  The African trypanosomiases , 1970 .

[136]  K. van Hoeve,et al.  The epidemiology of Trypanosoma rhodesiense sleeping sickness in Alego location, Central Nyanza, Kenya. I. Evidence that cattle may act as reservoir hosts of trypanosomes infective to man. , 1966, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[137]  R. B. Heisch,et al.  The isolation of Trypanosoma rhodesiense from a bushbuck. , 1958, British medical journal.